Baseline clinical characteristics of the study population (n = 89)
| Characteristics | |
|---|---|
| Age (yr)a | 57.8 (SD, 12.8) |
| Sex (male/female) | 43:46 |
| EGFR mutation–positive | 41 (46.1) |
| MGMT promoter methylation–positive status | 30 (33.7) |
| KPS at treatment initiation (%) | |
| >70 | 75 (84.3) |
| ≤70 | 14 (15.7) |
| Surgical extent (%) | |
| Gross total resection | 51 (57.3) |
| Partial resection | 28 (31.5) |
| Biopsy | 10 (11.2) |
| Maximal diameter (mm)a | 44.9 (SD, 15.4) |
| Adjuvant treatment (%) | |
| Standard CCRT+TMZ | 82 (92.1) |
| RT+TMZ | 11 (12.4) |
| OS (months)a | 17.7 (SD, 11.7) |
Note:—CCRT indicates concurrent chemoradiation therapy; RT+TMZ, hypofractionated RT for elderly patients with a hypofractionated radiation schedule (40 Gy in 15 fractions for 3 weeks) with TMZ.
↵a Data are expressed as means.